Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q-chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www. clinicaltrials.gov under identifiers NCT00466895 and NCT00546897.

Original languageEnglish
Pages (from-to)1002-1005
Number of pages4
Issue number5
StatePublished - Jan 29 2009


Dive into the research topics of 'Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13'. Together they form a unique fingerprint.

Cite this